BioCentury
ARTICLE | Company News

July 8 Company Quick Takes: Merck, Skyhawk in discovery deal; plus MorphoSys, BioMarin, Roche-Spark and Hanmi

July 8, 2019 10:59 PM UTC

Skyhawk, Merck in neurology, cancer deal
Skyhawk Therapeutics Inc. (Waltham, Mass.) and Merck & Co. Inc. (NYSE:MRK) parterned to discover, develop and commercialize small molecules capable of modulating RNA splicing discovered using Skyhawk’s SkySTAR platform for neurological diseases and cancer. Merck will have an option to exclusively license any candidates discovered under the deal, with Skyhawk eligible for $600 million per program target, comprising an upfront payment, opt-in fees and milestones, plus royalties.

Skyhawk expands Biogen deal ...